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http://dx.doi.org/10.1016/j.pedneo.2Dystrophinopathy is caused by mutations in the dystrophin gene at Xp21. Although manifesting
carriers of dystrophinopathy have been documented in adults, symptomatic dystrophinopathy in
female children is rare. We report on a 13-year-old girl with initial presentation of myalgia at
age 7 years and an incidental finding of increased transaminases and creatine kinase at regular
health check at age 12years. At age 13 years,manualmuscle testing revealed asymmetric bilateral
proximalweakness ofextremities. Slight calf hypertrophyandwinged scapulaewere found.Muscle
biopsy revealedamosaicpattern indystrophin immunostaining.Mutationanalysis of thedystrophin
gene revealed a novel de novo c.1150-2delAmutation. Accordingly, the patientwas found to be an
isolateddystrophinopathy carrier,manifesting limb-girdlepattern ofmuscleweakness in her child-
hood. This report suggests that dystrophinopathy should always be considered in female patients
with sporadicmyopathy. Dystrophin immunostaining andmutation analysis for thedystrophin gene
are necessary for final diagnosis, subsequent genetic counseling, and long-term care.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.h-Chuan 1st Road, Kaohsiung 807, Taiwan.
com.tw (C.-H. Wang).
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Dystrophinopathy with hyperCKemia 3751. Introduction Laboratory tests including lactate, complete blood count,Figure 1 (A) Motor unit potential (MUP) from the deltoid
posterior muscle showed myopathic pattern. Mean duration of
MUPs was 7 ms, and mean amplitude of MUPs was 389 mV. (B)
Spontaneous fibrillation potentials and positive wave were
observed.Mutations in the dystrophin geneat Xp21 lead to a spectrumof
phenotypes termed the dystrophinopathies, comprising
Duchenne muscular dystrophy (DMD), Becker muscular
dystrophy (BMD), and dilated cardiomyopathy (DCM). DMD is
the most severe phenotype, with onset of weakness in early
childhood, wheelchair dependence by the early teen years,
and death usually in the third decade due to cardiac and
respiratory failure. BMD is less commonand is amilder formof
the disease, in which patients are usually ambulatory until
adult years and may have a normal life span. Due to the X-
linked inheritance of this disorder, female carriers are not
supposed to display disease phenotypes. However, approxi-
mately 2.5-10% of female carriers have been shown to be
symptomatic, and 2% of them had no family history of
muscular dystrophy.1e3 A cohort study reported that themean
age of onset was 33 years, and symptoms were usually not
evident before age 16 years among manifesting female adult
carriers.4 Muscle weakness was the most common presenting
symptom to variable extent. Elevated serum creatine kinase
(CK) has been observed in half of DMD carriers.4 The most
common mechanisms accounting for manifesting female
carriers have been associated with a skewed X-inactivation
and X-autosome translocation.5,6 Herein, we report on a 13-
year-old girl with early onset of myalgia and incidental
finding of hypercreatine kinasemia (hyperCKemia), leading to
the discovery of isolated dystrophinopathy with a novel de
novomicrodeletion mutation (c.1150-2delA).
2. Case Report
This 13-year-old girl had no family history of neuromuscular
disease. She was a full-term baby born via normal sponta-
neous delivery. Her developmental milestones were normal
during infancy. However, she was able to walk indepen-
dently at the age of 18 months and claimed to be a slow
runner since early childhood. At the age of 7 years, she
easily felt fatigue and myalgia while dancing or running.
The condition was stationary and nonprogressive there-
after. At the age of 12 years, the patient was incidentally
found to have hypertransaminemia (glutamic-oxalacetic
transaminase: 89 IU/L, glutamic-pyruvic-transaminase:
59 IU/L, normal range: 10-42) at a regular health check
and subsequently elevated serum CK level (4,268 IU/L;
normal range <150 IU/L). In the meantime, she also
frequently complained of muscle cramps. It took 22 seconds
for her to run 100 m. Due to these findings, she was referred
to us for further investigation. On physical examination, the
girl had slight calf hypertrophy and mild contracture in the
right knee joint. Mild winged scapula was also noted, along
with symmetric facial expression and completely buried
eyelashes. Opthalmoplegia was negative. Toe and heel gait
were normal. Gowers’ sign was negative. The Achilles and
patellar tendon reflexes were both decreased. Grip and
percussion myotonia were both negative. Manual muscle
test (MMT) identified asymmetric muscle weakness,
predominantly in the right shoulder and pelvic girdle (MMT
score: 3 of 5 in the right extremities and 4 of 5 in the left
extremities).7 The patient had an MMT score of 5 in the
distal joints, including wrist and ankle joints.autoantibodies, thyroid function, and electrolytes all
revealed normal values. A routine urine test showed no
myoglobinuria. Electrocardiogram, echocardiogram, and
cognitive function also revealed no abnormalities. However,
electromyogram demonstrated myopathic change, showing
abnormal spontaneous activity with positive wave and
fibrillation, and small amplitude motor unit potential
(Figure 1). A computed tomography scan of muscle showed
no significant atrophic change. Thus, a muscle biopsy spec-
imen was obtained over the left biceps brachii for further
evaluation. On hematoxylin-eosin staining, dystrophic
changes including myofiber size variation, increased number
of internal nuclei, and scattered necrotic and regenerating
fibers were seen. Dystrophin immunostaining demonstrated
amosaic pattern, compatible with the findings for carriers of
dystrophinopathy8 (Figure 2). Immunohistochemical studies
for a-, b-, g-, and d-sarcoglycan revealed faint stainings at
the sarcolemma of dystrophin-deficient myofibers. Other
immunohistochemical stainings including a-dystroglycan,
merosin, dysferlin, vaceolin-3, and collagen VI all showed no
abnormalities. Meanwhile, a multiplex polymerase chain
reaction test combined with multiplex ligation-dependent
probe amplification was performed, and no deletion or
duplication of the dystrophin gene was detected. High-
resolution melting analysis with direct sequencing of the
dystrophin gene identified c.1150-2delA mutation, which
presented as a splicing sitemutation. The samemutationwas
not found in either of the patient’s parents (Figure 3). The
patient was not on any specific treatment but followed up
regularly for skeletal muscle and cardiac functions.93. Discussion
The initial presentation of disease in our patient was
myalgia when she was 7 years old. The disease became
noticeable because of elevation of liver aminotransferases
at the age of 12 years, which then led to the finding of
hyperCKemia and ultimately the diagnosis of muscular
dystrophy, although muscle weakness was still not prom-
inent. Our report suggests that dystrophinopathy should be
considered for female patients with persistent
Figure 2 (A) Hematoxylin-eosin staining of the muscle biopsy from the biceps brachii showed variations in myofiber size, an
increase in central nuclei, and scattered regenerating fibers and necrotic fibers. (B) An immunohistochemical study with anti-C-
terminus (DYS3) antibodies showed some muscle fibers with complete membrane staining and others with either reduced or
variable staining (mosaic pattern).
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dystrophinopathy.10
The spectrum of clinical presentations in manifesting
carriers is quite wide, ranging from a rapidly disabling DMD-
like phenotype to a very mild late-onset presentation.11
However, the most common symptom has been shown to
be muscular weakness. In 22 carriers with muscle weak-
ness, 18 (82%) carriers were predominately asymmetric
involved. Nine carriers (41%) had weakness limited to
shoulder girdles or upper arms.4 The clinical manifestation
somehow resembles limb girdle muscular dystrophy,
a heterogenous group of muscle disorders characterized by
predominant weakness and wasting of muscles of the pelvic
and shoulder girdle. Our report thus shows that muscle
biopsy remains a commonly useful and sometimes irre-
placeable method to differentiate dystrophinopathy from
other muscular dystrophies.11
Approximately 70% of DMD carriers have preclinically or
clinically evident myocardial involvement, and theFigure 3 The index patient carried dystrophin gene microdelet
deletion.incidence increases significantly with age. More than 90% of
carriers with cardiac involvement become symptomatic
after the age of 16 years.12 In a prospective study among 99
DMD/BMD carriers with a median follow-up of 9 years, 11
carriers (approximately 10%) with DCM were identified.
Nine of them eventually developed DCM during the follow-
up period. Cardiac abnormalities in DMD/BMD carriers are
progressive, as in patients with DMD/BMD.13 Therefore, we
should inform the patient of the risk of developing DCM and
the importance of regular cardiac assessments.14
Previous studies found no correlation between phenotype
and genotype in manifesting carriers.5,11 However, behavior
problems have been reported to be associated with deletion
or duplication of the dystrophin gene.5 In our patient,
mutation analysis revealed a splicing site mutation (c.1150-
2delA) that was supposed to cause deletion or insertion. Our
patient showed normal mental and cognitive functions.
Future studies with larger numbers of participants would be
necessary to further verify whether a genotype-phenotypeion (c.1150-2 del A). Her father and mother did not carry the
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dystrophin gene mutation, skewed X-inactivation is poten-
tially relevant to the phenotypic presentation in females.5,11
However, X-inactivation was not tested in our patient.
In conclusion, careful pattern recognition in dystrophin
immunostaining and dystrophin gene analysis is necessary
to make a correct diagnosis because prompt diagnosis of
dystrophinopathy carriers is important for further genetic
counseling, and prognostic information to patients and
families is essential for prophylactic monitoring cardiac
disease. In addition, because of subtle onset symptoms that
may be more likely to be misinterpreted in such girls, it is
important for clinicians to keep this disease in mind for
early identification of dystrophinopathy carriers.
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